메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
노은의 (서울대학교병원 약제부) 이유진 (서울대학교병원 약제부) 홍석민 (서울대학교병원 약제부) 김성환 (서울대학교병원 약제부) 서성연 (서울대학교병원 약제부) 조윤숙 (서울대학교병원 약제부) 박현진 (서울대학교 의과대학) 김보경 (서울대학교 의과대학) 홍경택 (서울대학교병원 소아청소년과) 최정윤 (서울대학교 의과대학 소아과학교실) 강형진 (서울대학교 의과대학) 이주연 (서울대학교 약학대학)
저널정보
한국병원약사회 병원약사회지 병원약사회지 제40권 제2호
발행연도
2023.5
수록면
171 - 182 (12page)
DOI
https://doi.org/10.32429/jkshp.2023.40.2.002

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background : Asparaginase is an important therapeutic agent in pediatric patients with acute lymphoblastic leukemia (ALL), but asparaginase-induced hypersensitivity reaction is one of the barriers to treatment completion. However, there have been limited studies investigating asparaginase-induced hypersensitivities in pediatric patients. The aim of this study was to investigate the incidence proportion and related factors of asparaginase- induced hypersensitivity reactions requiring treatment modification among pediatric patients with ALL. Methods : This cross-sectional study analyzed the pediatric ALL patients who received asparaginase treatment according to an in-hospital protocol between 2004-2021 at a single institution. The study calculated incidence proportions and treatment changes due to hypersensitivity reactions to different types of L-asparaginase. Risk factors of hypersensitivity were identified using generalized estimation equations. Results : Among the 269 eligible patients, 73 patients (27.1%) discontinued native E.coli asparaginase due to hypersensitivity. Hypersensitivity was observed with positive prior skin test before administration in 64 patients (23.8%) and allergic reaction after administration in 9 patients (3.3%). All of these patients switched to Erwina asparaginase but 10 patients (13.7%) among them showed hypersensitivity reactions to Erwina asparaginase. The related factors of asparaginase-induced hypersensitivity were identified as consolidation stage (odds ratio (OR) 14.70, 95% CI 1.70 – 126.99), long administration interval (OR 1.02, 95% CI 1.00 – 1.03), and high risk group for ALL (OR 3.35, 95% CI 1.21 – 9.27). Conclusion : The incidence proportion of hypersensitivity requiring treatment modification to Erwina asparaginase in pediatric patients was approximately 27%, and hypersensitivity reactions occurred in approximately 14% of patients after change to Erwina asparaginase. Consolidation stage, long administration interval, and high risk group for ALL were identified as related factors. Therefore, monitoring hypersensitivity reactions after asparaginase administration should be strengthened.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0